Atrys Health (XMAD:ATRY) Beta: 1.0128 (As of Jun. 25, 2026)


XMAD:ATRY Atrys Health SA XMAD:ATRY
66 GF Score
Price €2.57
GF Value €3.11
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Atrys Health Beta?

Atrys Health XMAD:ATRY -0.97% 66 Beta is 1.0128 as of Jun. 25, 2026. GuruFocus rates XMAD:ATRY with a GF Score™ of 66/100 and a GF Value™ of €3.11 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Atrys Health's Beta is 1.0128.


Atrys Health  (XMAD:ATRY) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Atrys Health Beta Related Terms


Atrys Health Beta Historical Data

* Premium members only.

The historical data trend for Atrys Health's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrys Health Beta Chart

Atrys Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.19 0.52 0.95 1.09

Atrys Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.86 0.95 0.86 1.09

XMAD:ATRY vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Atrys Health's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atrys Health Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrys Health's Beta distribution charts can be found below:

* The bar in red indicates where Atrys Health's Beta falls into.


XMAD:ATRY
66GF Score
Atrys Health SA XMAD:ATRY
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrys Health Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.0128 mean?
Atrys Health (XMAD:ATRY) has a Beta of 1.0128 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Atrys Health and its competitors.
Is Atrys Health's Beta too high?
Atrys Health's current Beta is 1.0128. Overall, Atrys Health has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's Beta compare to VRTX and REGN?
Atrys Health's Beta of 1.0128 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Atrys Health and its competitors. Atrys Health's current Beta is 1.0128. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.11, compared to a current price of €2.57 — trading 17.5% below its estimated fair value. The current Beta is 1.0128. Atrys Health's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current Beta is 1.0128 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atrys Health (XMAD:ATRY) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €2.57 is trading 17.5% below its estimated GF Value™ of €3.11. GuruFocus considers Atrys Health to be Modestly Undervalued.

Key valuation signals for XMAD:ATRY:

  • Beta: 1.0128
  • GF Value™: €3.11 vs. price of €2.57 (17.5% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Atrys Health Business Description

Other Exchanges A2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
66GF Score

Get the complete analysis for XMAD:ATRY

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.57
Price
€3.11
GF Value